ISCT22: BroadOak’s Poltilove remains bullish on CGT market despite downturn

May 9, 2022

Though gene therapy companies have been especially vulnerable to a public market downturn that's shaken the biotech sector, Bryan Poltilove, partner at BroadOak Capital Partners, remains "very bullish" on the fundamentals and the potential of the science.

Poltilove told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco that BroadOak's medium- to long-term investment strategy sees "great science" happening in the sector that's improving productivity and advancing cell and gene therapies, biologics, and other modalities.

BroadOak, which invests growth capital and provides investment banking services to companies operating in the life sciences tools, diagnostics, and biopharma services sectors, is an investor in ScienceBoard.net's parent company Science and Medicine Group.

Watch the video below to learn more.


ISCT president calls for cell and gene therapy education, training amid ‘talent shortage’
This week in San Francisco, industry, investors, physicians, patients, and regulators convened at the International Society for Cell & Gene Therapy (ISCT)...
ISCT working group weighs in on expanded access to CGT
Patricia Zettler, JD, associate professor of law at The Ohio State University, and chair of the International Society for Cell & Gene Therapy (ISCT) Expanded...
ISCT22: Cell therapy has potential to address unmet medical needs in orthopedics
Miguel Forte, CEO of Bone Therapeutics, and president-elect of the International Society for Cell & Gene Therapy (ISCT), spoke with ScienceBoard.net...
ISCT22: Tackling the ethical issues around cell and gene therapy
Unproven and unethical cell and gene therapies are a growing problem worldwide, according to Laertis Ikonomou, PhD, of the Department of Oral Biology...

Copyright © 2022 scienceboard.net

Last Updated 5/9/2022 6:22:20 AM